Prospective, Multi-Center All-Comer Biliary Canadian WallFlex Registry

NCT ID: NCT02261623

Last Updated: 2020-01-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

415 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-19

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to document stent functionality and practice patterns in Canada pertaining to indications for use and stent type selection for self-expanding biliary metal stents (SEMS) when used per standard of practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed to provide a report of these features related to the use of WallFlex metal biliary stents used per standard of practice in Canada.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Biliary Strictures

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Palliation

Palliative treatment of biliary strictures produced by malignant neoplasms, no intended surgery

WallFlex™ Biliary RX Fully Covered Stent System RMV

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures

WallFlex™ Biliary RX Partially Covered Stent System

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

WallFlex™ Biliary RX Uncovered Stent System

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Curative intent surgery

Palliative treatment of biliary strictures produced by malignant neoplasms, prior to curative intent surgery, with or without neoadjuvant therapy

WallFlex™ Biliary RX Partially Covered Stent System

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

WallFlex™ Biliary RX Uncovered Stent System

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Benign biliary strictures

Treatment of benign biliary strictures

WallFlex™ Biliary RX Fully Covered Stent System RMV

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures

WallFlex™ Biliary RX Partially Covered Stent System

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

WallFlex™ Biliary RX Uncovered Stent System

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Other indication

Other indication

WallFlex™ Biliary RX Partially Covered Stent System

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

WallFlex™ Biliary RX Uncovered Stent System

Intervention Type DEVICE

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

WallFlex™ Biliary RX Fully Covered Stent System RMV

For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures

Intervention Type DEVICE

WallFlex™ Biliary RX Partially Covered Stent System

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Intervention Type DEVICE

WallFlex™ Biliary RX Uncovered Stent System

For use in the palliative treatment of biliary strictures produced by malignant neoplasms.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject indicated for biliary metal stent placement per local standard of practice
* Age 18 or older
* Willing and able to comply with study procedures and follow-up schedule
* Willing and able to provide written informed consent to participate in study

Exclusion Criteria

* Subjects who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor
* Subjects who the investigator deems at risk for device or procedure related complications per the Directions for Use (DFU)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gurpal Sandha, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peter Lougheed Centre

Calgary, Alberta, Canada

Site Status

Royal Alexandra Hospital

Edmonton, Alberta, Canada

Site Status

University of Alberta Hospital

Edmonton, Alberta, Canada

Site Status

Providence Health - St. Paul's Hospital

Vancouver, British Columbia, Canada

Site Status

Victoria General Hospital

Victoria, British Columbia, Canada

Site Status

Queen Elizabeth II Health Sciences Center

Halifax, Nova Scotia, Canada

Site Status

Oakville-Trafalgar Memorial Hospital

Oakville, Ontario, Canada

Site Status

The Ottawa Hospital

Ottawa, Ontario, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Hopital Charles Le Moyne

Greenfield Park, Quebec, Canada

Site Status

CHUM - Hopital Saint-Luc

Montreal, Quebec, Canada

Site Status

CHUS Hotel Dieu

Sherbrooke, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

90921899

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.